CLIN.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...

Stats
今日成交量	1.79M
平均成交量	1.68M
市值	0.00
EPS	£0.0264 ( 2020-09-29 )
Last Dividend	£5.46 ( 2021-12-02 )
Next Dividend	£0 ( N/A )
P/E	0.410
ATR14	£0 (0.00%)

Clinigen Group PLC 相关性

10 最正相关
ARE.L	0.952
3USS.L	0.942
3ULS.L	0.939
XPD.L	0.936
MNZS.L	0.93
PBLT.L	0.925
GAW.L	0.91
GPH.L	0.891
IGE.L	0.878
AIBG.L	0.876

10 最负相关
YGEN.L	-0.965
DNM.L	-0.942
ECHO.L	-0.941
FRG.L	-0.932
EXR.L	-0.932
3NGL.L	-0.931
SIXH.L	-0.925
GIF.L	-0.921
VCAP.L	-0.911
MAST.L	-0.911

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Clinigen Group PLC 财务报表

Annual	2021
营收:	£523.60M
毛利润:	£197.90M (37.80 %)
EPS:	£0.233

FY	2021
营收:	£523.60M
毛利润:	£197.90M (37.80 %)
EPS:	£0.233

FY	2020
营收:	£504.30M
毛利润:	£220.00M (43.62 %)
EPS:	£0.103

FY	2019
营收:	£456.90M
毛利润:	£182.30M (39.90 %)
EPS:	£0.0400

Financial Reports:

No articles found.

Clinigen Group PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Clinigen Group PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.57 - good (95.68%) | Divividend Growth Potential Score: 4.52 - Potential for dividend initiation, but uncertain (9.63%)

Information

First Dividend	£0.600	2013-03-06
Last Dividend	£5.46	2021-12-02
Next Dividend	£0	N/A
Payout Date	2022-01-04
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	£45.62	--
Avg. Dividend % Per Year	0.20%	--
Score	3.37	--
Div. Sustainability Score	9.57
Div.Growth Potential Score	4.52
Div. Directional Score	7.04	--

Next Divdend (Est)
(2024-10-28)

£0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.37

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£5.60	0.64%
2019	£6.70	0.91%
2020	£7.61	0.83%
2021	£7.61	1.09%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TMI.L	Dividend Knight	2023-08-10	Quarterly	4	2.77%
LORD.L	Dividend Knight	2023-09-14	Semi-Annually	4	1.11%
CML.L	Dividend King	2023-08-03	Semi-Annually	32	2.93%
RNEP.L	Dividend Junior	2023-08-17	Quarterly	2	0.01%
HERC.L	Dividend Knight	2023-07-24	Semi-Annually	3	1.96%
AT.L	Dividend Junior	2023-05-25	Insufficient data to determine frequency	2	0.11%
VANL.L	Dividend Knight	2023-09-28	Annually	8	0.66%
MNP.L	Dividend Knight	2023-07-06	Quarterly	35	0.71%
DFDU.L	Dividend Knight	2023-09-14	Quarterly	2	0.70%
SHED.L	Dividend Knight	2023-06-29	Semi-Annually	9	2.67%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0579	1.500	8.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0284	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.0679	1.500	-0.357	-0.535	[0.1 - 1]
payoutRatioTTM	0.333	-1.000	6.67	-6.67	[0 - 1]
currentRatioTTM	1.752	0.800	6.24	4.99	[1 - 3]
quickRatioTTM	0.480	0.800	-1.884	-1.507	[0.8 - 2.5]
cashRatioTTM	0.480	1.500	8.45	10.00	[0.2 - 2]
debtRatioTTM	0.393	-1.500	3.45	-5.18	[0 - 0.6]
interestCoverageTTM	5.00	1.000	9.26	9.26	[3 - 30]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.130	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.937	-1.500	6.25	-9.38	[0 - 2.5]
grossProfitMarginTTM	0.378	1.000	7.03	7.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.112	1.000	9.77	9.77	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.108	1.000	-0.511	-0.511	[0.2 - 2]
assetTurnoverTTM	0.491	0.800	-0.0576	-0.0460	[0.5 - 2]
Total Score				9.57

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.63	1.000	6.10	0	[1 - 100]
returnOnEquityTTM	0.0679	2.50	-0.229	-0.535	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.130	2.00	9.96	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
payoutRatioTTM	0.333	1.500	6.67	-6.67	[0 - 1]
pegRatioTTM	25.76	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				4.52

Clinigen Group PLC

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.